Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders; it is characterized by polycystic ovaries, hyperandrogenism and chronic anovulation. To obtain a global view of those genes that might be involved in the development of this complex clinical disorder, we used recently developed cDNA microarray technology to compare differential gene expressions between normal human ovary and ovaries from PCOS patients. A total of 9216 clones randomly selected from a commercial human ovary cDNA library were screened. Among them, 290 clones showed differential expressions, including 119 known genes and 100 known or unknown expressed sequence tags (ESTs). Among 119 known genes, 88 were upregulated and 31 downregulated in the PCOS ovary, as compared with normal human ovary. These differentially expressed genes are involved in various biologic functions, such as cell division/apoptosis, regulation of gene expression and metabolism, reflecting the complexity of clinical manifestations of PCOS. The molecular characteristics established from our study will further our understanding of the pathogenesis of PCOS and help us to identify new targets for further studies and for the development of new therapeutic interventions.
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, being found in 4-7% of women of reproductive age and accounting for about 75% of anovulatory infertility. It is characterized by polycystic ovaries, hyperandrogenism and chronic anovulation (Knochenhauer et al. 1998) . PCOS is also associated with hirsutism, obesity, insulin resistance and compensatory hyperinsulinemia. Hyperinsulinemia results in an increased risk of cardiovascular disorders and a sevenfold increase in risk of non-insulin-dependent diabetes mellitus (NIDDM) . Many lipid abnormalities (most notably, low highdensity lipoprotein cholesterol levels and elevated triglyceride levels) and impaired fibrinolysis are seen in women with PCOS. Long-standing unopposed estrogen stimulation leads to an increased risk of endometrial carcinoma. PCOS is also associated with an increased rate (30-40%) of early pregnancy loss (Watson et al. 1993) . Early diagnosis of this syndrome, close long-term follow-up and screening for diabetes and cardiovascular diseases are warranted.
Familial clustering of PCOS cases suggests that genetic factors play an important role in PCOS's etiology (Legro et al. 1998) . Although the studies of familial cases of PCOS have produced results suggesting an autosomal dominant trait, the mode of inheritance has not been firmly established (Govind et al. 1999) . There are several reasons for this. First, genetic heterogeneity makes the genetic studies of PCOS hard to perform. Second, several pathways are implicated in the etiology of PCOS; therefore, several candidate genes may be responsible for this 'complex' genetic trait, making the identification of each contributing gene very difficult.
Until recently, the approach to understand the molecular basis of this complex syndrome was to study the functions of individual genes. However, since many pathways have been implicated in the etiology of PCOS, including the metabolic or regulatory pathways of steroid hormone synthesis, regulatory pathways of gonadotropin action, the insulin-signaling pathway, and pathways regulating glucose and lipid metabolism, expressions of numerous genes are coordinated both spatially and temporally during the development and progression of this disease. Earlier studies focused on the individual genes have not firmly established their roles in PCOS due to the complex nature of this disease (Jonard et al. 2002) . In this regard, a global profiling of gene expressions will yield useful information.
The newly developed functional genomic technologies, such as cDNA microarray, have enabled researchers to study the expressions of numerous genes simultaneously. As a well-established method and a powerful tool for massively parallel analysis of gene expression, microarray analysis has been applied in various biologic studies to identify differentially expressed genes. In this study, we used cDNA microarray technology to compare the expression patterns of 1000 genes in normal human ovaries and ovaries from PCOS patients, and identified genes that are up-or downregulated in PCOS patients. These results will help us to understand the pathogenesis of this complex clinical disorder at molecular level.
Materials and methods

Amplification of the cDNA library of human ovary
A human ovary 5 -STRETCH PLUS cDNA library (Cat: HL5025t, source of insert cDNA: 25 Caucasians, aged 16-80) was purchased from Clontech (Palo Alto, CA, USA). In the supplied TriplEx phagemid vector, the cloning sites are located within a plasmid that is embedded in a phage genome and flanked by loxP sites at the junctions. E. coli BM25·8 was used to circularize a complete plasmid from the recombinant phage at the loxP sites. To collect a set of representative clones, 12 000 positive phage plaques were randomly picked and amplified. Each TriplEx clone was transduced to a pTriplEx clone in E. coli BM 25·8, following the manufacturer's protocol (Clontech's Manual PT3003-1). Then the plasmid DNAs were extracted as previously described and stored at -70 C until use.
Construction of the human ovary cDNA microarray
To make DNA for spotting the microarray, each gene was amplified from plasmid clone by PCR ( TriplEx LD-insert Screening Amplimers, 5 -primer: CTCGGGAAGCGCGCCATTGTGTT GGT, 3 -primer: ATACGACTCACTATAGGG CGAATTGGCC), as described before . A total of 9216 PCR products with an average size of 1·0 kb (0·5-3·0 kb) was selected and stored in a 96-well format at -20 C. Two dots for each DNA sample were spotted with a total of 18 432 dots for 9216 samples on 8 12 cm nylon membranes, using an automatic arrayer (BioRobotics, Cambridge, UK). DNA was crosslinked to the nylon membrane by UV light. Eight housekeeping genes (ribosomal protein S9, -actin, glyceraldehyde-3-phosphate dehydrogenase, hypoxanthine phosphoribosyl transferase 1, phospholipase A 2 , ubiquitin C, ubiquitin carboxyterminal esterase L1 and H. sapiens mRNA for 23 kDa highly basic protein) were used as positive controls, while pTriplEx and PUC18 plasmid DNAs were used as negative controls . Twelve spots for each control cDNA were evenly distributed in the membranes.
Tissue collection and preparation of probes from normal and PCOS ovaries
Approval from the institutional ethics committee was granted before the initiation of this study. Samples of normal adult ovaries from women aged 30-40 years were obtained from the Body Donor Center (Nanjing Medical University). After macroscopic and histologic examinations, three ovary samples representing follicular and luteal phases respectively were selected for this study. Ovary tissues of three PCOS patients were obtained during surgical operations. These patients were recruited by the following criteria: amenorrhea, polycystic ovaries, hyperandrogenism or hirsutism. All the samples were histologically examined and stored in liquid nitrogen. Ovarian tissues from three PCOS patients and three normal adults were pooled separately and then homogenized. Total RNA was extracted by following Trizol RNA isolation protocol (Gibco BRL, Grand Island, NY, USA). Contaminating DNA was eliminated by DNase treatment. Total RNA was quantitated by measuring A260 and A260: 280 ratio. PolyA+ mRNA was then purified by the Oligotex mRNA Spin-Column system (Qiagen, Hilden, Germany). Afterwards, cDNA probes were prepared by reverse-transcription reaction containing [ 33 P]dATP. Labeled probes were quantified according to the manufacturer's protocol (NEN Life Science, Boston, MA, USA).
Hybridization and signal analysis
After prehybridization, the nylon membranes spotted with cDNA fragments were hybridized with 33 P-labeled cDNA probes from normal and PCOS ovaries in 6 ml hybridization solution (6 SSC, 0·5% SDS) at 65 C overnight. The membranes were washed three times with 20 ml wash solution (10 SSC, 0·5% SDS) at 65 C for 20 min. Membranes were then exposed to a phosphor screen overnight and scanned with a FLA-30000A fluorescent image analyser (Fuji Photo Film, Tokyo, Japan) with a 65 536 gray grade of 50 µm pixels. The radioactive intensity of each spot was analyzed with array gauge software (Fuji Photo Film, Tokyo, Japan). After the subtraction of background chosen from an area where no cDNA was spotted, clones with signal intensities of >2 were considered as positive to ensure that they were distinguished from background, with a statistical significance of >99·9% (array guage software). The data would be considered invalid if any of the 12 control spots for the same positive control cDNA had over a 1·0-fold difference in its intensity in one array. When the standard difference of the two dots for each DNA sample was less than 0·3, results would be accepted by the software.
Sequencing of differentially expressed clones and data analysis
A gene was considered differentially expressed if it met these two criteria: 1) beyond the 95% predicted regression line; 2) a difference in signal intensity of >2·0-fold between normal and PCOS samples. All clones consistent with the criteria were purified with R.E.A.L. Prep 96 system (Qiagen), and the inserts were sequenced with the MegaBase1000 automatic sequencing machine (Amersham Pharmacia Biotech, Bjorkgatan, Sweden). All sequencing reactions were performed twice for confirmation. 'Good' sequences referred to those containing less than 1% ambiguous bases in sequences longer than 100 bp. All resulting sequences were analyzed by DNASTAR (http:// www.dnastar.com) to get rid of repetitive and vector sequences. Standard BLAST searches were performed against sequences in GenBank. ESTs (expressed sequence tags) were considered as part of known genes if they shared at least 95% homology over at least 100 bp of DNA sequences. Sequences homologous to some repetitive elements were discarded. Those sequences sharing less than 95% homology with known ESTs were temporarily considered as novel ESTs. After a search against the Unigene database, all those differentially expressed ESTs were classified into seven groups based on their functional characteristics or cellular roles, which have been detailed previously (Adams et al. 1995) .
Reverse-transcription and semiquantitative real-time PCR analysis
To validate the difference of mRNA abundance in our differential expression profiling determined by cDNA microarray analysis, we selected four genes for semiquantitative real-time PCR analysis. To rule out genomic DNA contamination, PCR primer pairs were designed to span introns. The nucleotide sequences and annealing temperatures of the primers, and the length of the amplified fragments are shown in Table 1A .
We pooled three PCOS ovary RNA samples and three normal ovary RNA samples separately for reverse transcription with the Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Production of cDNA was then added to a 20 µl reaction mixture containing 10 µl of 2 TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 2 µl SYBR Green 1 (1:3200) (Molecular Probes, Eugene, OR, USA), and 2·5 pmol gene-specific primers according to the manufacturer's instructions. Real-time PCR was performed with ABI Prism 7000 (Applied Biosystems). Preliminary experiments were done for each primer pairs to determine the optimal primer concentration and annealing temperature that would yield the greatest amount of specific product with melting temperature (Tm) separable from primer-primer Tm. No template control was used for each reaction to ensure the absence of carryover DNA contamination. Results were analyzed using the relative C t method. The C t value, which is inversely proportional to the initial template copy number, is the calculated cycle number where the fluorescence signal emitted is significantly above background levels. Each sample was assayed twice, and the intra-assay coefficient of variation was less than 3%. -Actin from the same samples was amplified as an internal control for the normalization of starting amount of sample cDNA. The relative abundance of target gene mRNA between normal subjects and PCOS patients was then calculated.
Fold induction or repression by real-time PCR was measured and calculated after adjusting for -actin, using 2 -nnCt , where nC t =target gene C t --actin C t , and nnC t =nC tN (in normal human ovary) -nC tP (in PCOS ovary) (nnC t method, User Bulletin 2, Applied Biosystems). Statistics was done by two-sample t-test. Difference was considered to be statistically significant at 95% confidence level when P value was <0·05.
Western blot analysis
Cytosolic and nuclear proteins were extracted from two PCOS ovary samples and two normal ovary samples with the NE-PER Nuclear and Cytoplasmic Extract Kit (Pierce Biotechnology, Rockford, IL, USA). Aliquots of 50 µg protein extracts were loaded and separated by SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to a nitrocellulose membrane, which was blocked for 2 h at 25 C with 5% nonfat milk in PBS buffer (20 mM Tris, 500 mM NaCl and 0·01% Tween 20) 
C T P for C T value in PCOS ovary samples; C T N for C T value in normal ovary samples; SD for standard error. Note that a higher C T is indicative of a lower mRNA content.
and incubated with polyclonal antibodies to collagen I (diluted at 1:500), PDK4 (diluted at 1:250), hnRNPA2/B1 (diluted at 1:250), NR4A1 (diluted at 1:500), TGFBR2 (diluted at 1:250) and -actin (diluted at 1:250) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 C overnight. The blot was then visualized by enhanced chemiluminescence (Amersham Biosciences). The membrane was then scanned, and the signal intensity of each band was determined with ImageMaster Elite software (Amersham Biosciences). The relative levels of proteins in each sample were then normalized to -actin signal (signal intensity of specific protein/signal intensity of -actin).
Results
To investigate genes that are differentially expressed between normal and PCOS ovaries, we performed the cDNA microarray hybridization with probes prepared from normal human ovaries and ovaries from PCOS patients respectively. Positive signals were obtained from 8621 clones (93·5%) hybridized with probes from normal ovaries and 8476 clones (92%) hybridized with probes from PCOS ovaries. Figure 1 shows the scatter plot of hybridization intensity of double spots on PCOS ovary cDNA array. The equation R 2 =0·9789 indicates the reproducibility and reliability of our hybridization data.
Among the positive clones, 290 showed at least two times difference between normal and PCOS ovaries, with 200 clones expressed at a level of at least twofold higher in the PCOS ovaries and 90 clones at least twofold higher in normal ovaries. We sequenced all 290 clones and aligned consensus sequences by DNASTAR. Based on this analysis, there are 100 new or known ESTs, and 119 known genes. Among known genes, 88 expressed at a level of at least twofold higher and 31 at least twofold lower in PCOS ovaries than in normal ovaries (Tables 2 and 3) .
By their biologic functions, these known genes can be grouped into seven broad categories: 1) cell division (10%); 2) cell signaling/communication (20%); 3) cell structure and motility (6%); 4) cell/organism defense (4%); 5) gene/protein expression (37%); 6) metabolism (10%); and 7) unclassified (13%) (Fig. 2) . The detailed data for each group are also available at www.reprodlab.net/research_date/polycystic_ovary.htm.
To validate our cDNA microarry data, we selected four genes (NR4A1, PDK4, HIP-55 and SET) for semiquantitative real-time PCR analysis. These genes are differentially expressed in PCOS ovaries (Tables 2 and 3 ) and involved in various biologic functions that might have a role in the pathogenesis of PCOS. The sequences of primers used and relative changes in expression levels of these genes as determined by real-time RT-PCR are listed in Table 1A . A paired t-test showed that the differences in the levels of expression of these genes between normal subjects and PCOS patients are statistically significant (Table 1B) . The patterns of these gene expressions obtained from cDNA microarray and real-time RT-PCR analyses were similar, although the absolute ratios were different due to the potential difference in assay sensitivity and dynamics of these two assays (Fig. 3) .
To determine whether the differential gene expressions at mRNA levels seen between normal and PCOS ovaries are also reflected in their protein products, we did Western blot analysis to determine the protein levels of five genes (PDK4, hnRNPA2/B1, TGFBR2, collagen 1 and NR4A1), using protein samples from the ovaries of two normal subjects and two PCOS patients (Fig. 4A) . Levels of -actin in these samples were also measured and used to normalize sample loading. Afterwards, the ratio of relative levels of specific proteins in normal and PCOS ovaries was calculated ( Fig. 4B ) As shown in Fig. 4B , the differential protein expression patterns for these genes are similar to their relating mRNA expression patterns. Thus, our data from Western blotting analysis further validated our findings from cDNA microarray analysis. In this study, we used recently developed cDNA microarray technology to examine the differential gene expression patterns between normal and PCOS ovaries, and were able to identify several hundred genes expressed at changed levels in PCOS patients compared with normal subjects. These genes are involved in a wide range of biologic functions, including gene/protein expression, cell signaling/cell communication and metabolism. This picture is consistent with the complex nature of PCOS. Many genes identified in this study were found to be associated with hormone production, metabolism and apoptosis in other tissues, but their roles in human ovaries and PCOS have not been documented before. Furthermore, we found that different genes with similar functions changed their expression patterns as a group and might contribute to some aspects of PCOS development, such as impaired apoptosis, abnormal insulin-stimulated pathways, insulin resistance and anovulation. Insulin has numerous biologic functions in target tissues, such as glucogen synthesis, steroidogenesis, DNA synthesis and lipogenesis. There is increasing evidence that PCOS is associated with hyperinsulinemia, insulin-resistance and dyslipidemia. Insulin resistance has been observed in cultured skin fibroblasts derived from PCOS patients (Book & Dunaif 1999) . But peripheral insulin-resistance cannot fully explain the abnormal insulin action in PCOS ovary. In our study, we found that some genes involved in insulin functions changed their expression levels in PCOS ovary, including PDK4 (pyruvate dehydrogenase kinase 4) (Rosa et al. 2003 , Sugden et al. 2003 , PIGH (phosphatidylinositol glycan, class H) and UDP-GalNAcPP (UDPGalNAc pyrophosphorylase) (Muller et al. 1998 , Pouwels et al. 2002 . Pyruvate dehydrogenase complex (PDHC) regulates the oxidative metabolism of glucose, which can be inhibited by isoforms of PDK. Recently, increased PDK4 activity has been implicated in the pathogenesis of insulin resistance and non-insulin-dependent diabetes mellitus (NIDDM). In the muscle cell of NIDDM patients, PDK4 mRNA expression correlates negatively with glucose uptake rate, and decreases following the improvement of insulin sensitivity and the reduction of weight (Muller et al. 1998 , Rosa et al. 2003 . We found that PDK4 mRNA was upregulated in PCOS ovary, although we need to investigate whether this increased expression of PDK4 mRNA means the existence of insulin resistance in PCOS ovary. Some genes involved in insulin mitogenic pathway were also upregulated in PCOS ovary, mainly those in the MAPKs (mitogen-activated protein kinases) signaling pathway, such as RPS6KA2 (Dufresne et al. 2001) . Intrinsic selective insulin-resistance in PCOS ovary could be important to the development of metabolic and reproductive disturbance in this syndrome.
Apoptosis, a form of programmed cell death, is recognized as the mechanism of germ cell death and follicle atresia at all stages of ovary development and in the each cycle of folliculogenesis. The imbalance between apoptosis and proliferation affects the stages of follicle development, such as primary follicle pool formation, follicle recruitment and dominant follicle selection. PCOS patients have an obvious disturbance in their follicle development, since, in their ovaries, there are twice the number of primary and secondary follicles (Franks et al. 1998) , a subcortical necklaced array containing d10 follicles of 3-10 mm in diameter which are arrested at the small antral follicle stage and without dominant follicle, and thickened and hyperechogenic stroma and hyperproliferated theca-interstitial cells.
Previously, researchers suggested that the increased apoptosis of follicle cells contribute significantly to the premature arrest of follicle growth, but this alone cannot account for all three characteristics of disturbed follicle development in PCOS mentioned above. Furthermore, in vitro studies revealed that these arrested follicles are not atretic and show increased metabolic activity under normal culture condition (Nelson et al. 1999) . Our study indicates that there is a group of genes up-or downregulated in PCOS ovary that might result in reduced apoptosis. These genes include NR4A1 (nuclear receptor subfamily 4, group A, member 1) (Li et al. 2000) , HIP-55 (src homology 3 domaincontaining protein) (Chen et al. 2001 ) and HMGB1 (high-mobility group protein 1) (Stros et al. 2002) . They regulate apoptosis via different pathways such as the c-Jun N-terminal kinase signaling cascade (JNK)/NF-B, p53/BCL2/BAX and p73/c-myc (Watanabe et al. 2002 , Zhang et al. 2002 . Most of them finally influence apoptosis through the mitochondrial death signaling pathway, resulting in the defect in the release of cytochrome C (Tournier et al. 2000 , De Smaele et al. 2001 , Anning 2003 .
These data suggest that the overexpression of survival or antiapoptotic factors and downregulation of apoptosis inducers led to the blocking of follicle apoptosis and atresia in PCOS ovary. We hypothesize that the blocking of apoptosis and atresia affects follicle development at both gonadotropin-independent and -dependent stages, and contributes to the excessive recruitment of preantral follicles and accumulation of multiple small antral follicles as well as hyperproliferation of theca-interstitial cells.
The most interesting gene among this group is NR4A1, which is dramatically upregulated in normal adult ovary compared with fetal ovary (adult/fetal=7·1) (Xu & Diao et al., unpublished data) , but downregulated in PCOS ovary. NR4A1, also known as TR3, Nur77 or NGFI-B, has been confirmed as an inducer of apoptosis. It causes mitochondria to release cytochrome C (Li et al. 2000) . Considering that the major cell types Figure 4 Western blot analysis of proteins encoded by genes differentially expressed between normal and PCOS ovaries. (A) Western blotting for six gene products was carried out using specific antibodies, as indicated in Materials and methods. There are two samples from PCOS patients (P1 and P2) and two samples from normal subjects (N1 and N2). (B) The relative levels of gene and protein expressions between normal and PCOS ovaries determined by cDNA microarray and Western blotting. The y-axis represents the ratio of gene expressions at mRNA and protein levels between PCOS and normal ovaries. The signal intensity of -actin was used for the normalization of sample loading in Western blot analysis, as indicated in Materials and methods. Black columns represent data from Western blotting and white columns represent data from cDNA microarray.
expressing NR4A1 are thecal cells of follicles in different sizes, we suggest that the downregulation of NR4A1 might contribute to the hyperproliferation of theca cells from small antral follicles in PCOS ovary (Park et al. 2001) . As a nuclear receptor, NR4A1 mRNA expresses rapidly and transiently in granulosa cells of preovulatory follicles after the preovulatory luteinizing hormone (LH) surge in adult cycling rats (Park et al. 2001) , suggesting that NR4A1 may play a role in ovulation by initiating a cascade of expression of ovulation-specific genes in ovulatory follicles in response to LH surge. Considering that NR4A1 might play a protective role in atherogenesis, which is one of the long-term sequelae of PCOS, the expression pattern of NR4A1 in the PCOS patient's circulation system needs further investigation (Arkenbout et al. 2002) . These findings suggest that the downregulation of NR4A1 may affect multiple signal pathways and contribute to the development of various abnormalities in PCOS ovary simultaneously.
Theca cells are the major androgen-secreting cells in the human ovarian follicle. The enzymes involved in the synthesis of ovarian androgens, such as P450c17 and 3 -HSD, were observed in follicular theca cells, but not granulosa cells, in PCOS ovary (Kaaijk et al. 2000) . The hyperproliferation of theca cells, induced by blocked apoptosis and increased mitogenic actions, might contribute to the development of hyperandrogenism in PCOS.
Our cDNA microarray analysis also discovered a gene named SET (SET translocation) that can regulate androgen production by P450c17. Cytochrome P450c17 catalyzes 17 -hydroxylation during cortisol synthesis and 17,20-lyase activity during sex steroid production. 17,2-lyase activity, but not 17 -hydroxylation activity, can be inhibited by PP2A (protein phosphatase 2A). The serine phosphoprotein SET inhibits PP2A specifically and fosters 17,20-lyase activity (Pandey & Synthia 2003) . Since SET and PP2A are the posttranslational regulators of androgen biosynthesis, changes in their expression might contribute to the development of hyperandrogenism in PCOS.
Our study also revealed some other genes, such as C1 inhibitor (C1 inh) (Falus et al. 1990 , Han et al. 2002 , HNMT (histamine N-methyltransferase), prothrombin (Roach et al. 2002 , Yildiz et al. 2002 and TGFBRII (TGF-betaIIR alpha) (Qi et al. 1999) , which are differentially expressed in PCOS ovaries. The changed levels of expression of these genes might contribute to the impaired vascular permeability, fibrinolysis, and increased fibrogenesis in PCOS, as consistent with previous reports.
The differentially expressed genes we identified in this study also include some encoding initiation factors, elongation factors, general transcription factors and splicing factors. These factors control gene expression at levels of transcription, posttranscription and translation respectively. The upregulation of translation factors in PCOS ovary is consistent with the decreased apoptosis and increased mitogenesis (Wang et al. 2001) . Alternative splicing is another important mechanism for gene expression regulation. Alternative splicing can expand the coding capacity of limited number of genes to achieve the high molecular complexity needed to sustain normal body functions and facilitate responses to altered conditions (Hastings & Krainer 2001) . In our expression profiling, there are two members and one cooperator of serinearginine-rich (SR) proteins (SFRS11 (arginine/ serine-rich 11), TASR-1 (TLS-associated serinearginine-1) and SRRM2 (serine/arginine repetitive matrix 2/SRM300)) upregulated in PCOS ovary. Their precise functions in PCOS ovary are not yet known. But it has been reported recently that SR proteins can regulate the alternative splicing of members of the insulin signal pathway, such as IGF-1 and protein kinase C beta II, in response to metabolic and hormonal changes (Patel et al. 2001 , Smith et al. 2002 . In addtion to SR proteins, we also found genes of some other splicing factors (hnRNP A1 and hnRNP A2) upregulated in PCOS ovary. It has been reported that hnRNP A2 expression is increased during human endometrial hyperplasia or adenocarcinoma (Byrjalsen et al. 1999) . Since endometrial hyperplasia is one of the long-term sequelae of PCOS, the potential association of the upregulation of hnRNP A2 expression we found in PCOS ovaries with the increased risk of endometrial carcinoma in these patients warrants further study.
During the preparation of this paper, Wood et al. published their research on the gene expression profile in PCOS theca cells using Affymetrix GeneChip (Wood et al. 2003) . Our results are consistent with theirs on some genes, such as SH3-domain binding protein 5, C1-inhibitor/ SERPING 1 and DnaJ (HSP40) homolog, but differed in results on some other genes, such as SPARC-like 1 (mast9, hevin) and collagen I. We found these genes were upregulated in PCOS ovaries, while they found that the mRNA levels of these genes decreased in PCOS theca cells. Such a discrepancy could be due to the fact that the whole PCOS ovaries used in our study contain other types of cells, in addition to theca cells, which might have different levels of gene expressions.Therefore, future studies should take these factors into consideration.
In conclusion, we identified numerous genes that are differentially expressed in normal and PCOS ovaries. These genes are involved in various biologic functions, and their changed levels of expression might contribute to the pathogenesis of PCOS. Due to the complex nature of PCOS, no single factor can account for all aspects of this disorder. The global profiling of gene expressions will provide us with some insight into the molecular mechanism underlying clinical manifestations of PCOS.
